PTGX Q2 2024 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$39M-931.0% margin

Net Income

-$31M-734.7% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-98.4%

Cash Flow

Operating Cash Flow

$269M

Free Cash Flow

$269M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$615M

Total Liabilities

$73M

Stockholders' Equity

$541M

Cash & Equivalents

$356M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$39M	-$42M	+8.4%
Net Income	-$31M	-$38M	+20.4%

Revenue Segments

Development Services

$5M100%